spiruchostatin A (OBP-801) / Oncolys BioPharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Mekinist (trametinib) / Novartis
    Review, Journal:  "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). (Pubmed Central) -  Jul 23, 2022   
    Using the screening systems for agents that up-regulate the expression of p15, p27, and p21, we discovered the novel MEK inhibitor trametinib, the novel RAF/MEK inhibitor CH5126766/RO5126766/VS-6766, and the histone deacetylase inhibitor YM753/OBP-801, respectively...The combination of trametinib and the BRAF inhibitor dabrafenib was approved for advanced BRAF mutant melanoma in the USA, EU, Japan, and many other countries...In 2018, this combination was also approved for locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer in the USA after it had been granted Breakthrough Therapy Designation by the FDA. I describe here the characterization of our original screening system, RB-reactivator screening, by which these three molecular-targeting agents that advanced into clinical trials were identified.
  • ||||||||||  spiruchostatin A (OBP-801) / Oncolys BioPharma
    Preclinical, Journal, Epigenetic controller:  The histone deacetylase inhibitor OBP-801 has in vitro/in vivo anti-neuroblastoma activity. (Pubmed Central) -  Jun 28, 2022   
    Overall, OBP-801 induces M-phase arrest and apoptosis in neuroblastoma cells via mitotic catastrophe. Our results indicate that OBP-801 is a promising therapeutic agent with fewer adverse effects for patients with neuroblastoma.
  • ||||||||||  spiruchostatin A (OBP-801) / Oncolys BioPharma
    Journal:  Pluripotent epigenetic regulator OBP-801 maintains filtering blebs in glaucoma filtration surgery model. (Pubmed Central) -  Mar 18, 2021   
    OBP maintained the long-lived bleb without scar formation, and IOP was lower at 30 postoperative days compared with the vehicle control group. These findings suggest that OBP is an effective and useful candidate low-molecular-weight agent for improving wound healing and surgical outcomes in a rabbit model of GFS.
  • ||||||||||  spiruchostatin A (OBP-801) / Oncolys BioPharma
    Journal:  The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells. (Pubmed Central) -  Dec 17, 2020   
    The present results demonstrated that OBP-801 exerted therapeutic effects in myxofibrosarcoma in both single and concomitant administrations. Therefore, OBP-801 has potential as a novel treatment for myxofibrosarcoma.
  • ||||||||||  spiruchostatin A (OBP-801) / Oncolys BioPharma
    Trial completion date, Trial primary completion date, Metastases:  A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 13, 2019   
    P1a,  N=17, Active, not recruiting, 
    These results suggested that a combined treatment with OBP‑801 and amrubicin may have potential as a therapeutic strategy for SQCLC. Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Jun 2019
  • ||||||||||  spiruchostatin A (OBP-801) / Oncolys BioPharma
    Enrollment closed, Phase classification, Enrollment change, Trial primary completion date, Metastases:  A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Aug 17, 2018   
    P1a,  N=17, Active, not recruiting, 
    Trial completion date: Feb 2019 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Jun 2019 Recruiting --> Active, not recruiting | Phase classification: P1 --> P1a | N=36 --> 17 | Trial primary completion date: Feb 2017 --> Aug 2018